Electronic Supplementary Material (ESI) for Metallomics.

Gold(I)Phosphine Compounds as Parasite Attenuating Agents for Malaria Drug and Vaccine Development

Aloysious Ssemaganda, Leanne M. Low, Krista R. Verhoeft, Mathias Wambuzi, Barbara Kawoozo, Sharon B. Nabasumba, Juliet Mpendo, Bernard S. Bagaya, Noah Kiwanuka, Danielle I. Stanisic, Susan J. Berners-Price and Michael F. Good

Supporting Information



Fig. S1 Log dose response curves of [Au(d2pype)$_2$]Cl and auranofin, chloroquine and Riamet® for (A) Chloroquine sensitive *P. falciparum* strain 3D7 (B) Chloroquine resistant *P. falciparum* strain 7G8 (C) field isolate *P. falciparum* UGMCB-009 (D) field isolate *P. falciparum* UGMCB-013 and (E) *P. knowlesi*. Data is expressed as mean ± SEM.



Fig. S2 Clinical monitoring of BALB/c mice (n=5 per group) inoculated with 1x10^6 gold compound treated *P. chabaudi* AS pRBCs. Parasites were incubated for 80 minutes (A, D), 2 hours (B, E) and 3 hours (C, F). +++++ indicate that mice succumbed to the infection. Data is expressed as mean ± SEM.



Fig. S3 Parasitemia (A) and clinical scores (B) in BALB/c mice (n=5 per group) following 3 inoculations with $[Au(d2pype)_2]Cl$ or auranofin treated *P. chabaudi* AS pRBCs and challenge with $1x10^5$ *P. chabaudi AS*. +++++ indicate that mice succumbed to the infection. Data is expressed as mean ± SEM.